- The study investigated the 12-month neurological and psychiatric outcomes of semaglutide use in T2DM patients.
- Semaglutide, a GLP1-RA, has shown effectiveness in metabolic and cardiovascular outcomes.
- The study analyzed over 100 million health records in the US to assess the safety of semaglutide.
- Semaglutide was not linked to an increased risk of neurological or psychiatric conditions and showed benefits for cognitive deficits and nicotine dependence.
- The study supports semaglutide’s potential benefits for preventing cognitive deficits and substance misuse in T2DM patients.
Source link
Diabetes & Endocrinology, Psychiatry & Mental Health